Use of Nitrates as Antianginal Agents

  • Wilbert S. Aronow
Part of the Handbuch der experimentellen Pharmakologie / Handbook of Experimental Pharmacology book series (HEP, volume 40)


Angina pectoris due to coronary artery disease is generally considered to be chest pain due to myocardial ischemia which occurs because the myocardial oxygen demand exceeds the myocardial oxygen supply. An effective antianginal agent should relieve anginal pain either by improving the myocardial oxygen supply or by reducing the myocardial oxygen demand. In addition to relieving anginal pain, an ideal antianginal drug would also increase exercise performance, reduce electrocardiographic evidence of myocardial ischemia, prevent myocardial infarction, and prolong life. The following discussion will critically evaluate the efficacy of the nitrites as antianginal drugs.


Angina Pectoris Isosorbide Dinitrate Myocardial Oxygen Demand Anginal Attack Anginal Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aronow, W.S.: Drug evaluation—Chronic trials, in Ross, R.S. and Hoffman, F., editors: Myocardial Ischemia, International Congress Series No. 225, Amsterdam, 1971, Excerpta Medica, pp. 73–82.Google Scholar
  2. Aronow, W. S.: The medical treatment of angina pectoris II. Design of an antianginal drug study. Amer. Heart J. 84, 132–134 (1972a).PubMedCrossRefGoogle Scholar
  3. Aronow, W.S.: Medical treatment of angina pectoris. III. Pharmacology of sublingual nitrites as antianginal drugs. Amer. Heart J. 84, 273–275 (1972b).PubMedCrossRefGoogle Scholar
  4. Aronow, W.S.: The medical treatment of angina pectoris. IV. Nitroglycerin as an antianginal drug. Amer. Heart J. 8, 415–418 (1972c).CrossRefGoogle Scholar
  5. Aronow, W.S.: The medical treatment of angina pectoris. V. Long-acting nitrites as antianginal drugs. Amer. Heart J. 84, 567–569 (1972d).CrossRefGoogle Scholar
  6. Aronow, W.S.: The medical treatment of angina pectoris. IX. The medical management of angina pectoris. Amer. Heart J. 85, 275–278 (1973a).CrossRefGoogle Scholar
  7. Aronow, W.S.: Management of stable angina. New Engl. J. Med. 289, 516–520 (1973b).PubMedCrossRefGoogle Scholar
  8. Aronow, W.S., Chesluk, H.M.: Sublingual isosorbide dinitrate therapy versus sublingual placebo in angina pectoris. Circulation 41, 869–874 (1970a).PubMedGoogle Scholar
  9. Aronow, W.S., Chesluk, H.M.: Evaluation of nitroglycerin in angina in patients on isosorbide dinitrate. Circulation 42, 61–63 (1970b).PubMedGoogle Scholar
  10. Aronow, W.S., Kaplan, M.A.: Evaluation of propranolol and of isosorbide dinitrate in angina pectoris. Curr. Ther. Res. 11, 80–86 (1969).PubMedGoogle Scholar
  11. Battock, D.J., Alvarez, H., Chidsey, C.A.: Effect of propranolol and isosorbide dinitrate on exercise performance and adrenergic activity in patients with angina pectoris. Circulation 39, 157–169 (1969).PubMedGoogle Scholar
  12. Battock, D. J., Chidsey, C.A.: Isosorbide dinitrate in angina. Circulation 44, 1147 (1971) (Letter to the Editor).PubMedGoogle Scholar
  13. Bernstein, L., Friesinger, G.C., Lichtlen, P.R., Ross, R.S.: The effect of nitroglycerin on the systemic and coronary circulation in man and dogs. Myocardial blood flow measured with xenon. Circulation 33, 107–116 (1966).PubMedGoogle Scholar
  14. Burch, G.E., DePasquale, N.P.: Fresh nitroglycerin (glyceryl trinitrate). Amer. Heart J. 72, 842 (1966).PubMedCrossRefGoogle Scholar
  15. Cole, S.L., Kaye, H., Griffith, G. C.: Assay of anti-anginal agents I. A curve analysis with multiple control periods. Circulation 15, 405–413 (1957).PubMedGoogle Scholar
  16. Cole, S.L., Kaye, H., Griffith, G. C.: Assay of antianginal agents. A long-acting nitrate, psychic energizers and a tranquilizer. Amer. J. Cardiol. 11, 639–645 (1963).PubMedCrossRefGoogle Scholar
  17. Dagenais, G.R., Mason, R.E., Friesinger, G.C., Wender, C., Ross, R.S.: Exercise tolerance in patients with angina pectoris: Daily variation and effect of pentaerythritol tetranitrate. John Hopkins med. J. 125, 301–311 (1969).Google Scholar
  18. Detry, J.M., Bruce, R.A.: Effects of nitroglycerin on “maximal” oxygen intake and exercise electrocardiogram in coronary heart disease. Circulation 43, 155–163 (1971).PubMedGoogle Scholar
  19. Dewar, H.A., Horler, A.R., Newell, D.J.: A clinical trial of penta-erythritol tetranitrate, a khellin derivative (recordil), and iproniazid in angina of effort. Brit. Heart J. 21, 315–322 (1959).PubMedCrossRefGoogle Scholar
  20. Evans, W., Hoyle, C.: The comparative value of drugs used in the continuous treatment of angina pectoris. Quart. J. med. 2, 311–338 (1933).Google Scholar
  21. Fisch, S., DeGraff.A.C.: Coronary vasodilators. Dis Chest 44, 533–537 (1963).PubMedCrossRefGoogle Scholar
  22. Freis, E.D., Gaffney, T.E., Kirkendall, W., Marcus, F. I., Nickerson, M., Pearce, M.L.: Report of the panels on cardiovascular drugs from the drug efficacy study. Circulation 41, 149–151 (1970).Google Scholar
  23. Friend, D.G., O’Hare, J.P., Levine, H.D.: Action of triethanolamine trinitrate in angina pectoris. Amer. Heart J. 48, 775–779 (1954).PubMedCrossRefGoogle Scholar
  24. Ganz, W., Marcus, H.S.: Failure of intracoronary nitroglycerin to alleviate pacing-induced angina. Circulation 46, 880–889 (1972).PubMedGoogle Scholar
  25. Goldbarg, A.N., Moran, J.F., Butterfield, T.K., Nemickas, R., Bermudez, G.A.: Therapy of angina pectoris with propranolol and long-acting nitrates. Circulation 40, 847–853 (1969).Google Scholar
  26. Goldstein, R.E., Redwood, D.R., Epstein, S.E.: Isosorbide dinitrate in angina. Circulation 44, 1148–1149 (1971) (Letter to the Editor).Google Scholar
  27. Goldstein, R.E., Rosing, D.R., Redwood, D.R., Beiser, G.D., Epstein, S.E.: Clinical and circulatory effects of isosorbide dinitrate: comparison with nitroglycerin. Circulation 43, 629–640 (1971).PubMedGoogle Scholar
  28. Gorlin, R., Brachfeld, N., MacLeod, C., Bopp, P.: Effect of nitroglycerin on the coronary circulation in patients with coronary artery disease or increased left ventricular work. Circulation 19, 705–718 (1959).PubMedGoogle Scholar
  29. Horwitz, L.D., Gorlin, R., Taylor, W.J., Kemp, H.G.: Effects of nitroglycerin on regional myocardial blood flow in coronary artery disease. J. clin. Invest. 50, 1578–1584 (1971).PubMedCrossRefGoogle Scholar
  30. Horwitz, L.D., Herman, M.V., Gorlin, R.: Clinical response to nitroglycerin as a diagnostic test for coronary artery disease. Amer. J. Cardiol. 29, 149–153 (1972).PubMedCrossRefGoogle Scholar
  31. Kalmanson, G.M., Drenick, E.J., Binder, M. J., Rosove, L.: Pentaerythritol tetranitrate in the treatment of angina pectoris. Arch. intern. med. 95, 819–822 (1955).Google Scholar
  32. Klaus, A., Zaret, B., Pitt, B., Ross, R.S.: Comparative evaluation of sublingual long acting nitrates in angina pectoris. Amer. J. Cardiol. 31, 142 (1973) (Abstract).CrossRefGoogle Scholar
  33. Lange, R.L., Reid, M.S., Tresch, D.D., Keelan, M.H., Bernhard, V.M., Coolidge, G.: Nonatheromatous ischemic heart disease following withdrawal from chronic industrial nitroglycerin exposure. Circulation 46, 666–678 (1972).PubMedGoogle Scholar
  34. Livesley, B., Catley, P.F., Campbell, R.C., Oram, S.: Double-blind evaluation of verapamil, propranolol, and isosorbide dinitrate against a placebo in the treatment of angina pectoris. Brit. med. J. 1973 I, 375–378.CrossRefGoogle Scholar
  35. MacAlpin, R.N., Alvaro, A.B., Kattus, A.A.: Effect of propranolol and nitroglycerin on exercise tolerance in angina pectoris, in Kattus, A. A., Ross, G., Hall, V., editors: UCLA forum in medical sciences No. 13. Cardiovascular beta adrenergic responses, pp. 191–203. Berkeley-Los Angeles-London: University of California Press 1970.Google Scholar
  36. Mason, D.T., Braunwald, E.: The effects of nitroglycerin and amyl nitrite on arteriolar and venous tone in the human forearm. Circulation 32, 755–766 (1961).Google Scholar
  37. Master, A.M., Jaffe, H.L., Dack, S.: The drug treatment of angina pectoris due to coronary artery disease. Amer. J. med. Sci 197, 774–782 (1939).CrossRefGoogle Scholar
  38. Modell, W.: Clinical pharmacology of antianginal drugs. Clin. pharm. Ther. 3, 97–108 (1962).Google Scholar
  39. Needleman, P.: Tolerance to the vascular effects of glyceryl trinitrate. J. Pharmacol. exp. Ther. 171, 98–102 (1970).PubMedGoogle Scholar
  40. Needleman, P.: Oral nitrates: Efficacious? Ann. intern. med. 78, 458 (1973).Google Scholar
  41. Needleman, P., Lang, S., Johnson, E. M.: Organic nitrates: relationship between biotransformation and rational angina pectoris therapy. J. Pharmacol. exp. Ther. 181, 489–497 (1972).PubMedGoogle Scholar
  42. Nickerson, M.: Vasodilator drugs. In Goodman, L.S. and Gilman, A. (Eds.): The Pharmacological Basis of Therapeutics, p. 748. New York: Macmillan Co. 1965.Google Scholar
  43. Oram, S., Sowton, E.: Failure of propatylnitrate and pentaerythritol tetranitrate to prevent attacks of angina pectoris. Brit. med. J. 1961 II, 1745–1746.CrossRefGoogle Scholar
  44. Parker, J.O., West, R.P., DiGiorgi, S.: The effect of nitroglycerin on coronary blood flow and the hemodynamic response to exercise in coronary artery disease. Amer. J. Cardiol. 27, 59 – 65 (1971).PubMedCrossRefGoogle Scholar
  45. Riseman, J.E.F., Brown, M.G.: The duration of attacks of angina pectoris on exertion and the effect of nitroglycerin and amyl nitrite. New Engl. J. med. 217, 470–473 (1937).CrossRefGoogle Scholar
  46. Rowe, G.G.: Coronary vasodilator therapy for angina pectoris. Amer. Heart J. 68, 691–696 (1964).PubMedCrossRefGoogle Scholar
  47. Rowe, G.G., Chelius, C.J., Afonso, S., Gurtner, H.P., Crumpton, C.W.: Systemic and coronary hemodynamic effects of erythrol tetranitrate. J. clin. Invest. 40, 1217–1222 (1961).PubMedCrossRefGoogle Scholar
  48. Russek, H.I.: Propranolol and isosorbide dinitrate synergism in angina pectoris. Amer. J. Cardiol. 21, 44–54 (1968).PubMedCrossRefGoogle Scholar
  49. Sandler, G., Ilahi, M.A., Lawson, C.W.: Glyceryl trinitrate in angina pectoris. Lancet 1963 I, 1130–1136.CrossRefGoogle Scholar
  50. Schelling, J.L., Lasagna, L.: A study of cross-tolerance to circulatory effects of organic nitrates. Clin. pharm. Ther. 8, 256–260 (1967).Google Scholar
  51. Stipe, A.A., Fink, G.B.: Prophylactic therapy of angina pectoris with organic nitrates: Relationship of drug efficacy and clinical experimental design. J. clin. Pharmacol. 13, 244–250 (1973).PubMedGoogle Scholar
  52. Wang, J., Mathur, V.S., Messer, J. V.: Nitroglycerine induced flow maldistribution in coronary stenosis. Circulation 44 (Suppl II). 59 (1971) (Abstract).Google Scholar
  53. Williams, J. F., Jr., Glick, G., Braunwald, E.: Studies on cardiac dimensions in intact unanesthetized man. V. Effects of nitroglycerin. Circulatipn 32, 767–771 (1965).Google Scholar
  54. Willis, P.W. III, Duff, I. F.: Coronary vasodilating drugs. Med. clin. N. Amer. 41, 449–469,1957.PubMedGoogle Scholar
  55. Zelis, R., Mason, D.T.: Demonstration of nitrite tolerance: Attenuation of the vasodilator response to nitroglycerin by the chronic administration of isosorbide dinitrate. Circulation 40 (Suppl. III), 221 (1969) (Abstract).Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1975

Authors and Affiliations

  • Wilbert S. Aronow

There are no affiliations available

Personalised recommendations